🇺🇸 FDA
Patent

US 9249179

Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

granted A61PA61P1/16A61P3/00

Quick answer

US patent 9249179 (Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA) held by Arrowhead Madison, Inc. expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Madison, Inc.
Grant date
Tue Feb 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61P, A61P1/16, A61P3/00, A61P31/12